9 Reasons Menopause and HRT Raise Your Risk of Gallstones and Gallbladder Disease
The thing that gets me about this one is how completely off the radar it is. Women spend months researching HRT — reading about breast cancer risk, cardiovascular effects, bone protection — and gallbladder disease barely gets a footnote. Then they end up in A&E with what feels like a heart attack under their right ribs, and nobody connects the dots. This is one of those risks that deserves a proper conversation before treatment starts, not a surprised shrug afterward.
Learn more about Rose →Estrogen Makes Bile More Saturated With Cholesterol
Estrogen directly increases the amount of cholesterol secreted into bile while simultaneously reducing the bile salts and lecithin that normally keep it dissolved — a combination that creates what researchers call lithogenic, or stone-forming, bile. When cholesterol concentration in bile exceeds its solubility threshold, microscopic crystals begin to form, and over time those crystals aggregate into gallstones. This mechanism is well-established and is the same reason pregnancy, another high-estrogen state, is a recognised gallstone risk period.
Oral HRT Carries a Higher Gallbladder Risk Than Transdermal
When estrogen is swallowed as a tablet, it passes through the liver before entering circulation — a process called first-pass hepatic metabolism — which amplifies its effect on bile composition far more than a patch or gel that delivers estrogen directly into the bloodstream. Large observational studies, including data from the Women's Health Initiative, found that oral estrogen users had roughly twice the risk of gallbladder disease compared to non-users, while transdermal users showed a much smaller or negligible increase. This difference is one of the most clinically useful, and least-discussed, reasons route of administration matters.
Perimenopause Itself Creates a Window of Elevated Risk — Even Without HRT
Fluctuating and eventually declining estrogen during perimenopause alters bile composition in unpredictable ways, and the erratic hormonal swings of this phase appear to be particularly disruptive to gallbladder function. Studies comparing premenopausal and perimenopausal women have found measurable changes in bile lithogenicity that track with hormonal status, not just age. This means the risk window opens before any medication is introduced — a fact that helps explain why the peak incidence of symptomatic gallstones in women sits squarely in the late forties and early fifties.
Estrogen Slows Gallbladder Emptying, Letting Bile Stagnate
A healthy gallbladder contracts vigorously after meals to push bile into the small intestine, preventing any one batch of bile from sitting long enough to allow crystals to form. Estrogen reduces the sensitivity of gallbladder smooth muscle to cholecystokinin, the hormone that triggers this contraction, resulting in sluggish emptying and prolonged bile residence time. Bile that sits still long enough essentially concentrates itself — raising cholesterol saturation further and creating exactly the conditions in which stones nucleate and grow.
Weight Gain Around Menopause Compounds the Cholesterol Problem
The redistribution of body fat toward the abdomen that typically accompanies the menopause transition is associated with insulin resistance and increased hepatic cholesterol synthesis — meaning the liver produces and secretes more cholesterol into bile at precisely the time estrogen is already shifting the bile salt balance. Excess adipose tissue also produces estrone, a form of estrogen, which adds a secondary hormonal push toward lithogenic bile. The combination of central weight gain and hormonal change creates a compounding effect that is greater than either factor alone.
Progestogens in Combined HRT May Add a Further Layer of Risk
While estrogen is the primary driver, some research suggests that certain progestogens used in combined HRT also reduce gallbladder contractility, potentially worsening the stasis that estrogen already creates. The evidence here is less consistent than for estrogen alone, and effects appear to vary depending on the type and dose of progestogen used. It is an area where more research is genuinely needed, but it is worth noting that combined therapy does not appear to cancel out the gallbladder risk associated with estrogen.
Rapid Weight Loss — Common in Menopause Management — Is a Recognised Gallstone Trigger
When the body breaks down fat rapidly, the liver secretes the excess cholesterol directly into bile, sharply raising its lithogenicity during the weight loss period itself. Women who pursue calorie restriction or very low carbohydrate diets as part of managing menopause weight gain are entering a classically recognised gallstone risk window — and if their bile composition is already altered by estrogen, the risk stacks further. Gradual, sustained weight loss rather than rapid cycling is consistently associated with lower gallstone incidence.
Gallbladder Symptoms Are Frequently Mistaken for Other Menopause Complaints
The classic presentation of gallbladder disease — right upper quadrant pain, bloating, nausea, and discomfort after fatty meals — overlaps considerably with the bloating, digestive changes, and abdominal discomfort that many women attribute to perimenopause itself. This diagnostic blurring means gallbladder disease can go unrecognised for months or even years, progressing silently from sludge to stones to inflammation. A symptom that consistently worsens after meals and localises under the right ribcage deserves investigation rather than attribution to hormonal change alone.
Having a Prior History of Gallstones or Sludge Is a Meaningful Flag Before Starting Oral HRT
Women who have previously had gallstones, gallbladder sludge, or biliary colic are starting from a higher baseline risk, and adding oral estrogen to that picture is something that warrants explicit discussion with a doctor rather than a default prescription. Clinical guidelines in several countries acknowledge prior gallbladder disease as a factor that should prompt consideration of transdermal over oral estrogen when HRT is appropriate. This is not a reason to avoid HRT — transdermal options are not equivalent in gallbladder risk — but it is a reason the conversation needs to happen before treatment starts.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.